Clinical Comments

"IMI Healing Technologies offers patented LEP2000 Photonic & Laser Therapy System that features superior efficacy and versatility for pain relief and tissue healing."
Information from
IMIHT Press Release
Photonic and Laser
Therapy System LEP2000
Clinical Comments
Therapeutic Cold Lasers for Professionals
Laser Medical Technology Clinic Comments  

Laser Symbol Laser Therapy:
Facts Only

IMI Healing Technologies' prime mission is to bring the recognition and use by medical communities in North America and around the Globe of its LEP2000™ Photonic and Laser Therapy System, and to offer high-efficacy therapeutic devices based on scientifically and clinically proven healing properties of multi-modality photonic and laser therapy approaches.

Therapeutic laser LD100 with adjustable power 10mW up to 120mW, is clinically proven to provide significant immediate and sustainable pain relief. Laser LD100 features short treatment time - only a few seconds per point.

In the founders' opinion

"Our earliest research revealed and later clinical studies confirmed that high immediate and short-term pain reliefs are extremely important for good outcome of the entire course of treatment."
Dr. Norman Salansky, PhD,
President and Founder IMIHT

Low Energy Photon Therapy (LEPT)
in Johns Hopkins University

Johns Hopkins University has been using therapeutic system LEP2000 July 26, 2001

To Whom It May Concern:

As principal investigator I carried out a randomized, placebo controlled, double blind study using Low Energy Photon Therapy (LEPT) for venous leg ulcers.

The study's purpose was to evaluate the efficacy of LEPT in the treatment of chronic venous leg ulcers in a rigorous study. The LEPT system was provided a controllable three-dimensional photon distribution in the ulcer area, and was provided by International Medical Instruments, Inc., Toronto

A statistically significant, substantial difference (p=0.008) in ulcer healing between real and placebo LEPT groups was observed. Within the first three weeks of therapy, the average total ulcer area decreased by 45.2% in the LEPT-treated group. During the same interval, the average total ulcer area increased in size by 24% in the placebo group (p=0.003).

Other areas of LEPT applications:

Based on the preliminary data, I advised Dr. A. Chaiton, Professor, University of` Toronto, to test the efficacy of LEPT for median nerve regeneration in patients with carpal tunnel syndrome (CTS). The results of this study showed a substantial recovery of CTS symptoms and regeneration of median nerve as measured by objective nerve conduction test. I recommended submitting the results of this study to Lancet.

Collected clinical data on LEPT for skin ulcers, musculoskeletal pain, and carpal tunnel syndrome suggest that LEPT has significant potential to become an accepted medical treatment modality for above applications. Availability of home treatment devices for LEPT could promise substantial cost savings in rehabilitation medicine.

Sincerely yours,

Daniel N. Sauder, MD, FRCP(C), FACP
Professor and Chairman
Johns Hopkins University
Department of Dermatology
Baltimore, MD 21287-0900

1px 1px 1px 1px